Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Advanz Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RSD1235 | Drug | IV |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute | Infusion plus 1.5 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate safety | End of study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Use Central Contact | Astellas Pharma US, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Huntsville | Alabama | 35801 | United States | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21175515 | Derived | Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x. | |
| 20569725 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Atlanta |
| Georgia |
| 30322 |
| United States |
| Chicago | Illinois | 60637 | United States |
| Oak Lawn | Illinois | 60453 | United States |
| Boston | Massachusetts | 02135 | United States |
| Lansing | Michigan | 48910 | United States |
| Austin | Texas | 78756 | United States |
| San Antonio | Texas | 78229 | United States |
| Richmond | Virginia | 23249 | United States |
| Marshfield | Wisconsin | 54449 | United States |
| Buenos Aires | B8185SAN | Argentina |
| Buenos Aires | C1064AAR | Argentina |
| Buenos Aires | C1406GZL | Argentina |
| Buenos Aires | CP1280 | Argentina |
| Buenos Aires | CP1437 | Argentina |
| Corrientes | CP3400 | Argentina |
| De Buenos Aires | Argentina |
| Rosario | Argentina |
| Tulunaw | CP4000 | Argentina |
| Calgary | Alberta | T2N 4N1 | Canada |
| Ottawa | Ontario | K1Y 4E9 | Canada |
| Montreal | Quebec | G2K 4N1 | Canada |
| Montreal | Quebec | H2W 1T8 | Canada |
| Terrebonne | Quebec | J6V 2H2 | Canada |
| Aalborg | DK-9000 | Denmark |
| Esbjerg | DK-9800 | Denmark |
| Hjørring | DK-9800 | Denmark |
| Hvidovre | DK-2650 | Denmark |
| København NV | DK-2400 | Denmark |
| Køge | 4600 | Denmark |
| Berea Durban | 4001 | South Africa |
| Bloemfontein | 9301 | South Africa |
| Centurion | 0157 | South Africa |
| Parow | 7500 | South Africa |
| Somerset West | 7130 | South Africa |
| Westdene Bloemfontein | 9301 | South Africa |
| Malmö | SE-205-02 | Sweden |
| Mölndal | SE-431-80 | Sweden |
| Örebro | SE-701-85 | Sweden |
| Stockholm | SE-182-88 | Sweden |
| Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 Jun;159(6):1095-101. doi: 10.1016/j.ahj.2010.02.035. |
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C524581 | vernakalant |
Not provided
Not provided
Not provided